赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNY 赛诺菲安万特

休市中 04-26 16:00:00 EDT

49.13

-0.23

-0.47%

盘后49.13

+0.000.00%

19:12 EDT

最高49.47	最低48.17	成交量414.82万
今开48.84	昨收49.36	日振幅2.63%
总市值1,227亿	流通市值1,079亿	总股本24.97亿
成交额2.03亿	换手率0.19%	流通股本21.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":49.13,"timestamp":1714161600000,"preClose":49.36,"halted":0,"volume":4148180,"hourTrading":{"tag":"盘后","latestPrice":49.13,"preClose":49.13,"latestTime":"19:12 EDT","volume":3342,"amount":164189.56,"timestamp":1714173159106},"delay":0,"floatShares":2195692476,"shares":2497291352,"eps":2.376478,"marketStatus":"休市中","marketStatusCode":7,"change":-0.23,"latestTime":"04-26 16:00:00 EDT","open":48.84,"high":49.47,"low":48.17,"amount":202751821.72128,"amplitude":0.026337,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.376478,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":1,"listingDate":1025496000000,"adjPreClose":49.36,"adrRate":0.5,"dividendRate":0.041025,"preHourTrading":{"tag":"盘前","latestPrice":48.81,"preClose":49.36,"latestTime":"09:29 EDT","volume":137229,"amount":6699767.341116,"timestamp":1714138170027},"postHourTrading":{"tag":"盘后","latestPrice":49.13,"preClose":49.13,"latestTime":"19:12 EDT","volume":3342,"amount":164189.56,"timestamp":1714173159106},"volumeRatio":1.3685621397757115},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"2430479922","title":"赛诺菲业绩超预期，Dupixent今年销售额有望达130亿欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430479922","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430479922?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:33","pubTimestamp":1714037620,"startTime":"0","endTime":"0","summary":"财报数据还显示，赛诺菲Altuviiio第一季度的销售额达到1.22亿欧元，而分析师的普遍预期约为1.04亿欧元。赛诺菲重磅的哮喘治疗药物Dupixent的销售额与分析师预期相符，实现同比增长24.9%至28.35 亿欧元。哈德逊在与分析师们的业绩电话会议上表示，今年哮喘治疗药物Dupixent为赛诺菲带来的营收规模有望达到130亿欧元，全球约有85万名患者在服用该药。赛诺菲此后制定了雄心勃勃的扩张计划，以加强其多类型新药物的研发进程，其股价此后开始回升。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"db281c116d914585a115ec9827470da2","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109966.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2429617118","title":"赛诺菲(SNY.US)潜在“first-in-class”小分子疗法达3期主要终点 预计年底递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429617118","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429617118?lang=zh_cn&edition=full","pubTime":"2024-04-24 10:27","pubTimestamp":1713925624,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月24日，赛诺菲宣布其潜在“first-in-class”可逆布鲁顿氏酪氨酸激酶抑制剂rilzabrutinib达成LUNA 3临床3期试验的主要终点。赛诺菲预计在今年年底前向美国FDA和欧盟提交监管申请。据了解，赛诺菲致力于炎症与免疫学领域疗法的开发。今年2月，赛诺菲公布rilzabrutinib用于治疗中重度CSU患者的2期临床研究RILECSU的积极结果。数据表明rilzabrutinib显著改善了CSU成人患者的瘙痒、荨麻疹和风疹症状，这些症状无法通过H1抗组胺药得到充分控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108231.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418384693","title":"赛诺菲(SNY.US)公布2b期临床试验支持amlitelimab治疗特应性皮炎潜力结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2418384693","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2418384693?lang=zh_cn&edition=full","pubTime":"2024-03-11 16:09","pubTimestamp":1710144561,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国制药巨头赛诺菲公布了治疗多种炎症的药物amlitelimab 2b期研究STREAM-AD第二部分的积极结果。该结果显示，中度至重度特应性皮炎的成年人患者的体征和症状持续改善28周，这些患者先前对amlitelimab有反应并继续治疗。在停用amlitelimab的参与者中也观察到高应答率。安全性与研究第一部分一致，amlitelimab耐受性良好，未发现新的安全性问题。在所有剂量组中，持续amlitelimab治疗的患者在28周内保持较高的EASI-75和/或IGA 0/1、IGA 0/1和EASI-75应答率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1084434.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413419621","title":"赛诺菲(SNY.US)OX40L单抗在中国启动2期临床 针对特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2413419621","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2413419621?lang=zh_cn&edition=full","pubTime":"2024-02-21 16:41","pubTimestamp":1708504860,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国药物临床试验登记与信息公示平台官网最新公示，赛诺菲已经登记了一项国际多中心(含中国)2期开放性、长期研究，以在中度至重度特应性皮炎成人受试者中评价amlitelimab皮下给药的安全性和疗效。公开资料显示，全球范围内有多款靶向OX40信号通路的产品已经进入临床研究阶段，正在开发治疗肿瘤、特应性皮炎等适应症。在靶向OX40L的产品中，信达生物创新性免疫分子IBI356也正在中国开展治疗特应性皮炎的1期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1074415.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2412923254","title":"IPO前夜拿到PE“救命钱”，18A公司盛禾生物再度冲刺港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2412923254","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2412923254?lang=zh_cn&edition=full","pubTime":"2024-02-19 09:42","pubTimestamp":1708306979,"startTime":"0","endTime":"0","summary":"从17万到2个亿","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/e456f3a0-82db-4d95-970a-8cd678262e19.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/e456f3a0-82db-4d95-970a-8cd678262e19.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3708528","is_publish_highlight":false,"gpt_icon":0},{"id":"2408825931","title":"赛诺菲安万特2023财年实现净利润58.38亿美元，同比减少33.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2408825931","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2408825931?lang=zh_cn&edition=full","pubTime":"2024-02-03 00:21","pubTimestamp":1706890872,"startTime":"0","endTime":"0","summary":"12月31日，赛诺菲安万特公布财报，公告显示公司2023财年净利润为58.38亿美元，同比减少33.64%；其中营业收入为465.64亿美元，同比增加3.04%，每股基本收益为2.33美元。从资产负债表来看，赛诺菲安万特总负债573.99亿美元，其中短期债务25.63亿美元，资产负债比为0.01，流动比率为1.28。机构评级：截至2023年12月31日，当前有20家机构对赛诺菲安万特目标价做出预测，其中目标均价为56.75美元，其中最低目标价为43.32美元，最高目标价为66.60美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402030021238767cc0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402030021238767cc0d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408570687","title":"转型阵痛中，赛诺菲(SNY.US)Q4盈利不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408570687","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2408570687?lang=zh_cn&edition=full","pubTime":"2024-02-01 16:19","pubTimestamp":1706775577,"startTime":"0","endTime":"0","summary":"智通财经获悉，赛诺菲公布了第四季度财务业绩。赛诺菲公布第四季盈利略低于预估，因汇率波动不利，且流感疫苗需求不温不热。赛诺菲预计2024年业务每股收益将保持大致稳定。去年10月，赛诺菲出人意料地宣布将增加研发药物的支出，这需要放弃一些利润目标，赛诺菲股价因此暴跌。赛诺菲的新RSV药物Beyfortus部分弥补了这一缺口，该药物本季度的销售额超过预期，达到4.1亿欧元。赛诺菲表示，预计2024年和2025年后期临床试验的数量将增加50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1066653.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2405113747","title":"美股异动 | Inhibrx盘前涨超11%，赛诺菲斥资22亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2405113747","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2405113747?lang=zh_cn&edition=full","pubTime":"2024-01-23 17:40","pubTimestamp":1706002822,"startTime":"0","endTime":"0","summary":"1月23日，Inhibrx盘前涨超11%，$赛诺菲$将斥资22亿美元收购生物技术公司Inhibrx Inc.，这笔交易将使这家法国制药公司拥有一种治疗遗传性疾病α -1抗胰蛋白酶缺乏症的潜在疗法。两家公司在一份声明中表示，Inhibrx的股东将获得每股30美元的现金，并有权在达到监管里程碑后获得5美元的或有现金支付，同时目前每持有四股股份的股东将获得一股新Inhibrix股份。去年5月，Inhibrx的疗法获得了快速审查，并试图治疗儿童肝脏疾病最常见的遗传原因。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1059714.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2405150331","title":"深化创新药管线布局！赛诺菲(SNY.US)斥资22亿美元收购Inhibrx(INBX.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2405150331","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2405150331?lang=zh_cn&edition=full","pubTime":"2024-01-23 15:51","pubTimestamp":1705996266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲将斥资22亿美元收购生物技术公司Inhibrx Inc.，这笔交易将使这家法国制药公司拥有一种治疗遗传性疾病α -1抗胰蛋白酶缺乏症的潜在疗法。赛诺菲预计，这笔交易将利用现有现金资源融资。去年5月，Inhibrx的疗法获得了快速审查，并试图治疗儿童肝脏疾病最常见的遗传原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012315534287d92e63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012315534287d92e63&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404666353","title":"再生元制药(REGN.US)、赛诺菲(SNY.US)重磅抗炎药再获FDA积极监管决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2404666353","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2404666353?lang=zh_cn&edition=full","pubTime":"2024-01-17 21:31","pubTimestamp":1705498286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月17日，再生元制药和赛诺菲宣布，美国FDA更新其重磅白细胞介素-4和白细胞介素-13抑制剂Dupixent治疗特应性皮炎的标签，增加了针对12岁及以上、手和/或脚症状未受控制的中度至重度特应性皮炎患者的疗效和安全性数据。此前，Dupixent单抗已被FDA批准治疗包括特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉病、结节性痒疹和嗜酸性食管炎等疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1056980.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2402748021","title":"大手笔赞助奥运会 赛诺菲(SNY.US)希望因此改善公众形象","url":"https://stock-news.laohu8.com/highlight/detail?id=2402748021","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2402748021?lang=zh_cn&edition=full","pubTime":"2024-01-10 19:10","pubTimestamp":1704885000,"startTime":"0","endTime":"0","summary":"赛诺菲(SNY.US)希望通过赞助奥运会，可以吸引新的人才，奖励现有员工，并摆脱这家法国制药商保守的形象。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240110/20240110190802_58992.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240110/20240110190802_58992.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1053178.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2400596748","title":"阿斯利康(AZN.US)和赛诺菲(SNY.US)预防婴儿RSV感染的药物今日在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2400596748","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2400596748?lang=zh_cn&edition=full","pubTime":"2024-01-02 19:10","pubTimestamp":1704193855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今天，阿斯利康和赛诺菲宣布其共同开发与商业化的长效单克隆抗体乐唯初正式获得中国国家药品监督管理局批准上市。该药物用于预防新生儿和婴儿由呼吸道合胞病毒引起的下呼吸道感染。尼塞韦单抗预计将于2024-2025年RSV感染季在中国上市。阿斯利康和赛诺菲于2017年3月宣布达成尼塞韦单抗合作开发及商业化协议。根据协议条款，阿斯利康负责产品的开发与生产，赛诺菲负责产品的商业化和营收计量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240102191412878c19b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240102191412878c19b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2393179441","title":"赛诺菲(SNY.US)停止靶向CEACAM5 ADC药物Tusamitamab ravtansine全球临床开发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2393179441","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2393179441?lang=zh_cn&edition=full","pubTime":"2023-12-21 17:01","pubTimestamp":1703149294,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲表示，该公司将停止其靶向CEACAM5的新型抗体偶联药物Tusamitamab ravtansine的全球临床开发项目。赛诺菲表示，独立数据监测委员会发布，与多西他赛相比，Tusamitamab ravtansine作为单药治疗无法满足无进展生存的双重主要终点。该公司表示，将继续探索基于Tusamitamab抗体的ADC和CEACAM5研究在几种癌症中的潜力。一直以来，CEACAM5作为结直肠癌临床诊疗中常用的肿瘤标志物来帮助诊断和检测肿瘤发展。Tusamitamab ravtansine是目前针对CEACAM5靶点研究进展最快的同类首创药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1043499.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2389043771","title":"隔夜美股全复盘(12.6)| 三大股指小幅波动，涨跌不一，纳斯达克中国金龙指数收跌1.5%；苹果涨逾2%，总市值重返3万亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2389043771","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2389043771?lang=zh_cn&edition=full","pubTime":"2023-12-06 07:16","pubTimestamp":1701818167,"startTime":"0","endTime":"0","summary":"三大股指小幅波动，涨跌不一，纳斯达克中国金龙指数收跌1.5%；苹果涨逾2%，总市值重返3万亿美元","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/670877","is_publish_highlight":false,"gpt_icon":0},{"id":"2389723922","title":"赛诺菲(SNY)与Aqemia达成价值1.4亿美元的药物研究协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2389723922","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2389723922?lang=zh_cn&edition=full","pubTime":"2023-12-05 23:10","pubTimestamp":1701789055,"startTime":"0","endTime":"0","summary":"金吾财讯 | 当地时间12月5日，法国制药公司Aqemia发表声明称，已与赛诺菲(SNY)达成一项价值高达1.4亿美元的多年期研究合作协议。Aqemia公司将利用其生成式人工智能和深度物理算法及平台设计新型药物分子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=7764d895b219398fd0a9fb6be66730b8","is_publish_highlight":false,"gpt_icon":0},{"id":"2389694711","title":"支出计划引发股价暴跌 赛诺菲(SNY.US)CEO压力山大","url":"https://stock-news.laohu8.com/highlight/detail?id=2389694711","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2389694711?lang=zh_cn&edition=full","pubTime":"2023-12-05 16:34","pubTimestamp":1701765265,"startTime":"0","endTime":"0","summary":"赛诺菲首席执行官Paul Hudson正面临巨大压力。投资者对媒体表示，Hudson的任期从去年开始，将于2026年到期。Lyons对赛诺菲股价暴跌感到意外，但他也表示Hudson言论出乎意料，而且缺乏解释。近年来，由于股东担心赛诺菲过于依赖其畅销的抗炎药Dupixent，该股表现落后于竞争对手。Tema ETF的Song表示，为了换取2025年以后更高的利润前景，盈利增长推迟一年可能是可以接受的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1033537.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2386715032","title":"赛诺菲(SNY.US)Dupixent3期临床试验达到主要终点 显著降低慢阻肺恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=2386715032","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2386715032?lang=zh_cn&edition=full","pubTime":"2023-11-28 08:34","pubTimestamp":1701131682,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月28日，赛诺菲和再生元联合宣布，重磅IL-4/IL-13抑制剂Dupixent在治疗慢性阻塞性肺病的第二项3期临床试验中达到主要终点，显著降低中重度COPD患者的疾病恶化。据悉，Dupixent有望成为治疗这一严重疾病的首款获批生物制品。Dupixent在此试验中的安全性基本符合其在先前批准适应症中的已知安全性。不良事件的总体发生率非常接近，Dupixent组为67%，安慰剂组为66%。导致死亡的AE发生率为Dupixent组2.6%，安慰剂组1.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1029941.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2386188867","title":"赛诺菲(SNY.US)Dupixent在慢性肺病二期试验中疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2386188867","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2386188867?lang=zh_cn&edition=full","pubTime":"2023-11-27 17:04","pubTimestamp":1701075846,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲处方药Dupixent最新研究表明，它能有效帮助慢性肺疾病患者改善呼吸功能和恢复肺功能，并有望为这款畅销药品开拓更多增长空间。赛诺菲周一发布的消息显示，Dupixent在针对慢性阻塞性肺病患者的第二期关键性研究中展现出显著疗效。然而，在一项名为Notus的高级别临床试验中，Dupixent使患者COPD恶化速率相比安慰剂组下降了34%。而在此前的Boreas试验中，这一下降比例为30%。此外，这家法国药企今年前9个月通过Dupixent获得了77亿欧元销售额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112717051784492474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023112717051784492474&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2381567495","title":"赛诺菲(SNY.US)因涉嫌操纵市场遭到法国监管机构调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2381567495","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2381567495?lang=zh_cn&edition=full","pubTime":"2023-11-07 21:16","pubTimestamp":1699362960,"startTime":"0","endTime":"0","summary":"智通财经获悉，法国金融检察官正在调查赛诺菲(SNY.US)涉嫌操纵市场。据一位消息人士透露，初步调查于今年3月展开，涉及传播与该制药商财务沟通有关的误导性信息。赛诺菲表示，它不了解调查事件，其财务信息是“准确、精确和真诚的”。媒体报道称该调查与2017年重磅药物Dupixent的推出有关。这种治疗哮喘和皮肤的药物自那以来成为赛诺菲最畅销的药物。这种抗体疗法的销售额今年可能超过100亿美元，如果这种药物治疗慢性肺部疾病的前景得到证实，销售额将远远超过100亿美元。截至发稿，该公司股价美股盘前下跌1.33%，报44.64美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1021238.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":0.0611},{"period":"1month","weight":-0.0083},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.1391},{"period":"1year","weight":-0.1241},{"period":"ytd","weight":-0.0121}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.022852},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.021195},{"month":3,"riseRate":0.818182,"avgChangeRate":0.033135},{"month":4,"riseRate":0.681818,"avgChangeRate":0.026088},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.000285},{"month":6,"riseRate":0.47619,"avgChangeRate":-0.014662},{"month":7,"riseRate":0.47619,"avgChangeRate":0.016345},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.015597},{"month":9,"riseRate":0.545455,"avgChangeRate":0.009477},{"month":10,"riseRate":0.545455,"avgChangeRate":0.000171},{"month":11,"riseRate":0.636364,"avgChangeRate":0.001886},{"month":12,"riseRate":0.727273,"avgChangeRate":0.03338}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}